06/12/2022
New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that new data show that the...
29/09/2022
Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic...
27/09/2022
MinervaX announces that EMA has awarded PRIME Status for its Group B Streptococcal vaccine MinervaX, a privately held Danish biotechnology company,today announces that EMA has awarded PRIME status for its vaccine against Group B Streptococcus (GBS).PRIME is aimed at...
30/03/2022
Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the...
08/03/2022
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate...
22/02/2022
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases,...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments